Praxis Precision Medicines Inc (PRAX) Stock Price, Quote & News

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-ty...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 300 8460

Website: praxismedicines.com

Address:

99 High Street, 30th Floor, Boston, United States

JarvisFlow Jun. 12 at 11:00 AM

Needham has adjusted their stance on Praxis Precision Medicine ( $PRAX ), setting the rating to Buy with a target price of 80.

0 · Reply

StockConsultant Jun. 3 at 1:29 PM

$PRAX Praxis Precision Medicines stock, watch for an upside gap breakout at https://stockconsultant.com/?PRAX

0 · Reply

JarvisFlow Jun. 2 at 5:45 PM

Oppenheimer has adjusted their stance on Praxis Precision Medicine ( $PRAX ), setting the rating to Outperform with a target price of 97.

0 · Reply

JarvisFlow May. 7 at 11:00 AM

Chardan Capital has adjusted their stance on Praxis Precision Medicine ( $PRAX ), setting the rating to Buy with a target price of 80.

0 · Reply

Armonica423 May. 6 at 6:42 PM

$PRAX CYDY

0 · Reply

Rage_Against_The_Machine May. 2 at 9:14 PM

$PRAX drops Phase 3 EMERALD trial design for relutrigine - 160 patients, 16-week study. EMBOLD extension data (n=12) shows sustained seizure reduction through 11 months. PRAX-100 ASO candidate nomination coming mid-2025. Cash runway to 2027 means they can afford to keep these trial codenames coming. https://www.sec.gov/Archives/edgar/data/1689548/000168954825000062/prax-20250502.htm

1 · Reply

StockConsultant May. 2 at 12:38 PM

$PRAX Praxis Precision Medicines stock, watch for an upside gap breakout above 40 at https://stockconsultant.com/?PRAX

0 · Reply

JarvisFlow May. 1 at 12:00 PM

HC Wainwright & Co. has adjusted their stance on Praxis Precision Medicine ( $PRAX ), setting the rating to Buy with a target price of 105.

0 · Reply

JarvisFlow Apr. 8 at 11:30 AM

Needham has updated their rating for Praxis Precision Medicine ( $PRAX ) to Buy with a price target of 85.

0 · Reply

NVDAMillionaire Mar. 29 at 11:56 AM

$PRAX Digging deep into PRAX's pipeline. Ulixacaltamide looking promising for essential tremor. Vormatrigine epilepsy trials could be game-changer. Relutrigine showing impressive seizure reduction. Strong cash position gives them runway. Watching these catalysts closely in 2025. great article: https://beyondspx.com/article/praxis-precision-medicines-nasdaq-prax-a-promising-biotech-innovating-cns-therapies

0 · Reply

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2025, 3:26 PM EDT - 6 weeks ago

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

May 2, 2025, 8:30 AM EDT - 7 weeks ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 8, 2025, 8:00 AM EDT - 2 months ago

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Apr 3, 2025, 5:00 PM EDT - 2 months ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Mar 3, 2025, 11:03 PM EST - 4 months ago

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)

Feb 28, 2025, 8:00 AM EST - 4 months ago

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Feb 3, 2025, 5:00 PM EST - 5 months ago

Praxis Precision Medicines to Present at Two February Investor Conferences

Jan 12, 2025, 9:00 PM EST - 5 months ago

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Dec 18, 2024, 8:00 AM EST - 6 months ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dec 5, 2024, 8:30 AM EST - 7 months ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB STOK WGS

Dec 3, 2024, 8:00 AM EST - 7 months ago

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Nov 6, 2024, 5:00 PM EST - 8 months ago

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

Nov 6, 2024, 11:56 AM EST - 8 months ago

Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 7:30 AM EST - 8 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 1, 2024, 8:00 AM EDT - 8 months ago

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

Sep 4, 2024, 8:00 AM EDT - 10 months ago

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

Sep 3, 2024, 7:30 AM EDT - 10 months ago

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Sep 2, 2024, 5:00 PM EDT - 10 months ago

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

Aug 14, 2024, 3:14 PM EDT - 11 months ago

These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results

Aug 13, 2024, 2:47 PM EDT - 11 months ago

Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript

Aug 5, 2024, 4:01 PM EDT - 11 months ago

Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

May 17, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

May 13, 2024, 7:00 AM EDT - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 10, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

Mar 28, 2024, 12:20 AM EDT - 1 year ago

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Mar 26, 2024, 1:34 PM EDT - 1 year ago

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Mar 26, 2024, 6:30 AM EDT - 1 year ago

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Praxis Precision Medicines to Host PRAX-628 Program Update

Mar 5, 2024, 7:00 AM EST - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 1, 2024, 8:00 AM EST - 1 year ago

Praxis Precision Medicines to Participate in TD Cowen's 44th Annual Health Care Conference

Jan 11, 2024, 7:30 AM EST - 1 year ago

Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering

Nov 28, 2023, 7:00 AM EST - 1 year ago

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

Nov 21, 2023, 4:00 PM EST - 1 year ago

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 16, 2023, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

Nov 7, 2023, 7:00 AM EST - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Oct 2, 2023, 1:17 PM EDT - 1 year ago

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

Sep 27, 2023, 4:15 PM EDT - 1 year ago

Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023

Aug 28, 2023, 7:00 AM EDT - 1 year ago

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

Aug 9, 2023, 7:00 AM EDT - 2 years ago

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 8, 2023, 7:00 AM EDT - 2 years ago

Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study

Aug 3, 2023, 4:12 PM EDT - 2 years ago

Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference

Jul 24, 2023, 7:01 PM EDT - 2 years ago

Praxis Precision Medicines: Long List Of Failures And Mixed Data

Jun 22, 2023, 7:00 AM EDT - 2 years ago

Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities

Jun 15, 2023, 11:58 PM EDT - 2 years ago

Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering

Jun 9, 2023, 7:00 AM EDT - 2 years ago

Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA

Jun 2, 2023, 9:00 AM EDT - 2 years ago

Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference

JarvisFlow Jun. 12 at 11:00 AM

Needham has adjusted their stance on Praxis Precision Medicine ( $PRAX ), setting the rating to Buy with a target price of 80.

0 · Reply

StockConsultant Jun. 3 at 1:29 PM

$PRAX Praxis Precision Medicines stock, watch for an upside gap breakout at https://stockconsultant.com/?PRAX

0 · Reply

JarvisFlow Jun. 2 at 5:45 PM

Oppenheimer has adjusted their stance on Praxis Precision Medicine ( $PRAX ), setting the rating to Outperform with a target price of 97.

0 · Reply

JarvisFlow May. 7 at 11:00 AM

Chardan Capital has adjusted their stance on Praxis Precision Medicine ( $PRAX ), setting the rating to Buy with a target price of 80.

0 · Reply

Armonica423 May. 6 at 6:42 PM

$PRAX CYDY

0 · Reply

Rage_Against_The_Machine May. 2 at 9:14 PM

1 · Reply

StockConsultant May. 2 at 12:38 PM

$PRAX Praxis Precision Medicines stock, watch for an upside gap breakout above 40 at https://stockconsultant.com/?PRAX

0 · Reply

JarvisFlow May. 1 at 12:00 PM

HC Wainwright & Co. has adjusted their stance on Praxis Precision Medicine ( $PRAX ), setting the rating to Buy with a target price of 105.

0 · Reply

JarvisFlow Apr. 8 at 11:30 AM

Needham has updated their rating for Praxis Precision Medicine ( $PRAX ) to Buy with a price target of 85.

0 · Reply

NVDAMillionaire Mar. 29 at 11:56 AM

0 · Reply

Moneywheel Mar. 26 at 7:18 AM

$ANRO I the replies I am getting are the same...I have been here long enough to learn how to identify stocks with an huge upside potential. Unfortunately I do not have the crystal ball to name the exact date that the stock may react higher triggering momentum and turning parabolic because this is almost impossible unless your family name is Musk or Trump....but $TNXP, $PRAX, $ABEO..to name a few had similar patterns back in 2023 and the run up were splendid. Again, you gotta know the drill and understand that sizing is important. Smallcaps are a complement for your trading strategy approaches. If you base your success only trading smallcaps the odds for you to fail and run out of cash are clearly against you. Paytience will pay out on that one....

1 · Reply

St0ckMyst1c Mar. 17 at 3:33 PM

$CRVO $PRAX FDA SUBMISSION IS COMING 👇👇👇🔥🔥🔥

0 · Reply

_www_larval_com_ Mar. 4 at 8:53 PM

$CRML 4%[34%] $ATCH 4%[-15%] $CALC 3%[-3%] $PRAX -3%[5%] $EDBL -3%[-17%] most notable movement into the final minutes of trading.

0 · Reply

jParkz Mar. 4 at 8:00 PM

$PRAX News Article Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences https://marketwirenews.com/news-releases/praxis-precision-medicines-to-participate-in-five-up-6845462945045092.html $PRAX

0 · Reply

moneygrab001 Mar. 4 at 7:59 PM

$PRAX morgan stanley said 80...50 will come soon

0 · Reply

moneygrab001 Mar. 4 at 6:44 PM

$PRAX people will buy this at 60 in 3 weeks

0 · Reply

moneygrab001 Mar. 4 at 6:07 PM

$PRAX 50% discount shares at this point as per morgan stanley

0 · Reply

Eagles78 Mar. 4 at 2:07 PM

$PRAX I didn’t mention cash in my original post. The CFO should do it from a strategic standpoint.

0 · Reply

TomMac64 Mar. 4 at 2:07 PM

$PRAX they do t need the money !

1 · Reply

Eagles78 Mar. 4 at 2:06 PM

$PRAX @TomMac64 If the CFO thinks the stock has a threat of going back to $10 in the short-run why not do an offering at $33? Makes sense don’t you think? Unless you think the stock will recover.

0 · Reply

TomMac64 Mar. 4 at 9:35 AM

$PRAX I’m sorry I was incorrect $470M into 28’ and that’s a facto 🙂 factor

0 · Reply

TomMac64 Mar. 4 at 9:33 AM

$PRAX Plenty of cash into 27’ $440M that’s a fact so stop the lies !

0 · Reply

Market Cap	862.42M
Revenue (ttm)	8.55M
Net Income (ttm)	-182.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,138.25%
Debt to Equity Ratio	0.00

Volume	217,700
Avg Vol	361,734
Day's Range	N/A - N/A
Shares Out	20.37M
Stochastic %K	13%
Beta	2.60
Analysts	Strong Sell
Price Target	$97.67